SRPT insider buying and SEC filings, explained
Sarepta Therapeutics, Inc. · CIK 873303
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$417K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Mar 12, 2026 | Sale | Stephen Mayo (Director) sold 7,239 shares at $17.02 ($123K). Holdings down 80% to 1,765 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 13, 2026 |
| Dec 16, 2025 | Sale | Ian Michael Estepan (President / COO) sold 13,187 shares at about $22.31 ($294K). Holdings down 6% to 193,300 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 18, 2025 |
35 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow SRPT in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.